Infusion Laboratory: Protocol 5 (Flupenthixol) - 14

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00000349
Recruitment Status : Unknown
Verified December 2002 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
First Posted : September 21, 1999
Last Update Posted : January 11, 2017
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to evaluate clinical safety issues pertaining to flupenthixol, to cocaine, and to their interaction, and to determine how pretreatment with flupenthixol modifies the subjective as well as physiological effects of cocaine. Taken together, these relatively D-1 selective agents can help determine the extent to which DA-1 binding affects the reinforcing effects of stimulants.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Drug: Flupenthixol Phase 1

Study Type : Interventional  (Clinical Trial)
Enrollment : 0 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Infusion Laboratory: Protocol 5 (Flupenthixol)

Primary Outcome Measures :
  1. Degree of drug craving
  2. History, incidence and amount of drug use
  3. Type and severity of stimulant withdrawal symptoms
  4. Characterization of study population
  5. Population incidence of symptoms of depression, po
  6. Frequency and intensity of drug use and sexual beh
  7. Evidence of change in neurophysiology and brain ac
  8. Evidence of change in subjective responses to coca
  9. Clinical physiological response to cocaine challen
  10. Degree to which study medication influences change

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00000349

United States, California
Friends Research Institute
Los Angeles, California, United States, 90025
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Walter Ling, M.D. Friends Research Institute, Inc. Identifier: NCT00000349     History of Changes
Other Study ID Numbers: NIDA-3-0010-14
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: January 11, 2017
Last Verified: December 2002

Keywords provided by National Institute on Drug Abuse (NIDA):
cocaine dependence

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Flupenthixol decanoate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action